Quinidine


Generic Medicine Info
Administration
Should be taken with food. Best taken at meal times.
Contraindications
Complete AV block (w/o functional pacemaker), myasthenia gravis, history of quinidine/quinine-associated thrombocytopenic purpura.
Special Precautions
Patient w/ 2nd degree AV block (w/o functional pacemaker), digitalis intoxication, severe intraventricular conduction defect, prolonged QT interval or history of torsades de pointes, myocarditis, uncompensated heart failure, severe myocardial damage, pre-existing asthma, muscle weakness, infection w/ fever. Renal and hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor cardiac function including BP and ECG (during IV admin), CBC, liver and renal function tests regularly during long-term admin.
Adverse Reactions
GI irritation (e.g. nausea, vomiting, diarrhoea, oesophagitis, abdominal pain), resp difficulties, pruritus, urticaria, rash, thrombocytopenic purpura, blood dyscrasias, granulomatous hepatitis, lupus-like syndrome; cinchonism w/ tinnitus, impaired hearing, visual disturbances, confusion, vertigo, headache, delirium; syncope. Rarely, anaphylaxis, fever.
Potentially Fatal: Torsades de pointes, toxic epidermal necrolysis.
Drug Interactions
Reduced renal clearance w/ drugs that alkalinise the urine (e.g. carbonic-anhydrase inhibitors, Na bicarbonate, thiazide diuretics). Increased plasma levels w/ cimetidine, amiodarone, ketoconazole, verapamil. Decreased plasma levels w/ nifedipine. Increased hepatic elimination w/ rifampicin, phenytoin, phenobarbital. Potentiates the action of depolarising (e.g. suxamethonium) and nondepolarising (e.g. pancuronium) neuromuscular blocking agents, and warfarin. May increase plasma levels of digoxin, haloperidol, procainamide.
CIMS Class
Antimalarials / Cardiac Drugs
ATC Classification
C01BA01 - quinidine ; Belongs to class Ia antiarrhythmics.
Disclaimer: This information is independently developed by CIMS based on quinidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in